237 filings
Page 6 of 12
8-K
xpcdmjua
17 Oct 19
ADMA Biologics Announces Publication of an
7:49am
8-K
3io 1z5rzu
7 Oct 19
ADMA Biologics Announces Data Presented at IDWeek 2019
7:28am
8-K
rg5if9u 0ut8
3 Oct 19
ADMA Biologics Announces Poster Presentation at IDWeek 2019
7:38am
8-K
r38rg041etd8
2 Oct 19
Regulation FD Disclosure
7:38am
8-K
mjhc n3183cs6n2134
23 Sep 19
ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference
7:38am
8-K
ei0vav4dh2
5 Sep 19
Entry into a Material Definitive Agreement
5:00pm
8-K
fdjx66mo0yi q6ycdxd
23 Aug 19
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
n9tt7a jh
22 Aug 19
Other Events
8:08am
8-K
2zz62qrvrg0 f6ysms
8 Aug 19
ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results
7:08am
8-K
ugtidmpcp2 kfp1s709
8 Jul 19
All Aspects of the Biotest Therapy Business Unit (“BTBU”) Acquisition Are Successfully Completed
4:45pm
8-K
yr81qy
6 Jun 19
Other Events
6:01am
8-K
1h4cxs
5 Jun 19
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
js58ce7btnkx
29 May 19
ADMA Biologics to Present at Upcoming Investor Conferences
7:15am
8-K
zy6axfen
21 May 19
ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:30pm
8-K
mt886
17 May 19
ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock
7:15am
8-K
dpvlsyv1ue7 q9kvqi4v
15 May 19
Other Events
4:30pm
8-K
hcib1m
10 May 19
Other Events
7:05am
8-K
b5gxlebyb80o11
8 May 19
ADMA Biologics Reports First Quarter 2019 Financial Results
4:28pm
8-K
qfvvx hhiddt5ngtk4
3 May 19
ADMA Biologics Elects to Draw-Down $27.5 Million in Capital from Existing
5:00pm
8-K
qjpbiuah
17 Apr 19
ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections
7:15am